(NASDAQ: DYN) Dyne Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 67.48%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 40.64%.
Dyne Therapeutics's earnings in 2025 is -$423,801,000.On average, 17 Wall Street analysts forecast DYN's earnings for 2026 to be -$475,763,315, with the lowest DYN earnings forecast at -$604,662,595, and the highest DYN earnings forecast at -$347,920,938. On average, 12 Wall Street analysts forecast DYN's earnings for 2027 to be -$425,403,330, with the lowest DYN earnings forecast at -$670,447,646, and the highest DYN earnings forecast at -$275,937,295.
In 2028, DYN is forecast to generate -$286,777,689 in earnings, with the lowest earnings forecast at -$746,030,470 and the highest earnings forecast at $86,980,234.